Metastatic Triple-Negative Breast Cancer: Applying Treatment Advances to Personalized Care

Sara A. Hurvitz, MD, FACP, Director of the Breast Cancer Clinical Trials Program at the David Geffen School of Medicine at UCLA, and a prominent authority on TNBC, provides perspectives on personalized care plans for patients with metastatic TNBC, efficacy and safety of emerging treatments, strategies to improve quality of life for patients with metastatic TNBC, and much more! Start the activity now!

STATEMENT OF NEED

With an estimated 284,200 new cases per year, breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United States (ACS, 2021). Numerous subtypes of invasive breast cancers exist, including triple-negative breast cancer (TNBC), an aggressive subtype which accounts for approximately 15% of all cases. Without the expression of estrogen, progesterone, and human epidermal growth factor 2 (HER2) receptors, TNBC does not respond to hormone therapies or targeted agents, leading to limited treatment options and a poor prognosis compared with other types of invasive breast cancer. In addition, treatment planning can be complicated by individual patient characteristics, response to prior therapy, and cumulative doses and toxicity. With a dearth of effective treatment options, 5-year survival rates for TNBC range from 91% for localized disease to only 12% for distant disease (ACS, 2021).

TARGET AUDIENCE

Oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).

LEARNING OBJECTIVES

Evaluate clinical and molecular factors that can inform personalized care plans for patients with metastatic TNBC
Differentiate emerging efficacy and safety data on novel therapies for metastatic TNBC
Assess strategies to manage treatment-related adverse events and improve quality of life for patients with metastatic TNBC
FACULTY